Eledon Pharmaceuticals Inc. (ELDN)
Eledon Pharmaceuticals, Inc. (ELDN) Discusses Updated Long-term Data From Phase 2 BESTOW Clinical Trial in Kidney Transplantation Transcript
Eledon Pharmaceuticals, Inc. (ELDN) Discusses Updated Long-term Data From Phase 2 BESTOW Clinical Trial in Kidney Transplantation Transcript
Is Eledon Pharmaceuticals (ELDN) Outperforming Other Medical Stocks This Year?
Here is how Eledon Pharmaceuticals, Inc. (ELDN) and Galderma Group AG - Unsponsored ADR (GALDY) have performed compared to their sector so far this year.
Is BillionToOne, Inc. (BLLN) Stock Outpacing Its Medical Peers This Year?
Here is how BillionToOne (BLLN) and Eledon Pharmaceuticals, Inc. (ELDN) have performed compared to their sector so far this year.
Eledon Pharmaceuticals, Inc. (ELDN) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript
Eledon Pharmaceuticals, Inc. ( ELDN ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 12, 2025 10:30 AM EST Company Participants Steven Perrin - President, Chief Scientific Officer & Non Independent Director Conference Call Participants Vamil Divan - Guggenheim Securities, LLC, Research Division Presentation Vamil Divan Guggenheim Securities, LLC, Research Division All right. Thanks, everyone, for joining us here on the Second Annual Guggenheim Healthcare Innovation Conference.
Eledon Pharmaceuticals, Inc. (ELDN) Discusses Phase II BESTOW Trial Results and Advances in Transplantation Immunosuppression Transcript
Eledon Pharmaceuticals, Inc. ( ELDN ) Discusses Phase II BESTOW Trial Results and Advances in Transplantation Immunosuppression November 7, 2025 8:00 AM EST Company Participants David-Alexandre Gros - CEO & Non Independent Director Eliezer Katz - Chief Medical Officer Steven Perrin - President, Chief Scientific Officer & Non Independent Director Paul Little - Chief Financial Officer Conference Call Participants Thomas Smith - Leerink Partners LLC, Research Division Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division Rami Katkhuda - LifeSci Capital, LLC, Research Division Vamil Divan - Guggenheim Securities, LLC, Research Division Robert LeBoyer - NOBLE Capital Markets, Inc., Research Division Gum-Ming Lowe - Craig-Hallum Capital Group LLC, Research Division Yi Chen - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the Eledon Pharmaceuticals Phase II BESTOW Results Conference Call.
Best Momentum Stocks to Buy for July 14th
ELDN, KDDIY and PENG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 14, 2025.
New Strong Buy Stocks for July 14th
WIT, KNOP, PENG, ELDN and KDDIY have been added to the Zacks Rank #1 (Strong Buy) List on July 14, 2025.
What Makes Eledon Pharmaceuticals (ELDN) a New Buy Stock
Eledon Pharmaceuticals (ELDN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Eledon: A Company With Good Early Data In Kidney Transplant Rejection And A Full Balance Sheet
Eledon Pharmaceuticals' lead candidate, tegoprubart, shows promise in improving kidney function post-transplant, potentially becoming the new standard-of-care over tacrolimus. With a significant total addressable market, tegoprubart could address over 25,000 new kidney transplant patients annually, translating to a $6B market opportunity. The upcoming Phase 2 study data in Q4 2025 is a critical milestone, with potential for transformative value and a possible $6B buyout valuation.
Eledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management Business
Eledon Pharmaceuticals' Tegoprubart, a second-gen anti-CD40L antibody, shows promise in preventing organ rejection without thromboembolic risks, addressing unmet needs in kidney and islet cell transplantation. Early trials indicate Tegoprubart's safety and efficacy, with no major side effects and better kidney function compared to current standards like tacrolimus. Eledon has a market cap of $264mn, a cash balance of $78mn, and a cash runway of 7-8 quarters, but remains a high-risk investment.
Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart
Positive phase 1b biomarker and eGFR data achieved from phase 1b study using tegoprubart for prevention of organ rejection in kidney transplant patients. Top-line data from the phase 2 BESTOW study, using tegoprubart for prevention of organ rejection in kidney transplant patients, expected in Q4 of 2025. The organ transplant immunosuppressant drugs market is expected to reach $6.4 billion by 2030.
Penny Stock Picks: 3 Companies Poised to Graduate to the Big Leagues
Penny stocks sometimes get a bad rep due to their inherent risk. They are cheap but are considered highly volatile and have a low chance of providing substantial profit.
